10-12 October, 2017
Frankfurt, Germany

Day One
Wednesday 11th October, 2017

Day Two
Thursday 12th October, 2017

Chair’s Opening Remarks

  • Peter Traber Chief Executive Officer & Chief Medical Officer, Galectin Therapeutics

Confidently Diagnose & Stratify NASH Patient Populations

Identification of Biomarkers for the Diagnosis of NASH

  • Dean Hum Chief Scientific Officer, Genfit


• Explore novel biomarkers for a better diagnosis of NASH
• Discover new scores that enable the discrimination of NASH patients from NAFLD
• Review the development of a companion tool for Elafibranor

The Importance of High Precision Imaging Biomarkers in NASH Drug Development


• Precision Imaging biomarkers in NASH: difference between diagnosis and drug development
• Review the latest imaging biomarkers for drug development in NASH: Impact on decision making

Morning Refreshments & Networking

Enhance NASH Compound Preclinical Development Strategy

Prosecuting Metabolic Modulators as NASH Therapeutics

  • James Trevaskis Principal Scientist & Head of In Vivo Pharmacology , MedImmune


• Discuss current standard rodent models that reflect different disease pathologies
• Robustly interpret pathology in mouse models and the benefit of a biopsy
• Translate the effect of NASH therapeutics from mice to man

Determine Protective Effects of FXR Agonists on Kidney Function in Obesity

  • Zhibo Gai Post Doc , University Hospital of Zurich


• Learn that obesity is not only a risk factor for NASH, but also an independent risk factor for chronic kidney disease, leading to glomerulosclerosis and renal insufficiency
• Gain an in-depth understanding of how renal lipid accumulation and lipotoxicity play an important role in the pathogenesis of renal injury
• Review the development of ligands of the farnesoid X receptor (FXR), which attenuate kidney damage induced by obesity by reducing renal lipid accumulation and activating protective signalling pathways
• Discuss how the protective effect of FXR ligands on kidney function opens up new indications for this class of therapeutic ligands, for instance in the context of kidney donation by obese donors

Think Tank Roundtables


More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

Lunch & Networking

Past is Prologue: Case Study of The Development of Obeticholic Acid for NASH and What’s Ahead for NASH Development


  • OCA entered clinical development for NASH nearly a decade ago
  • OCA was one of the earliest agents to advance into phase 3 testing for NASH; at the time regulatory pathways and endpoints were largely uncharted territory
  • Today, there are nearly a dozen agents in phase 2/3 testing for NASH; development pathways have changed dramatically in the intervening years
  • Current and future agents face a dynamic regulatory landscape with nascent technologies; great potential exists but risks remain and in some cases, are greater than faced by OCA over the past decade

Moderator Feedback & Audience Debate


Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion to share ideas and best practice.

Explore Developments in Clinical Trial Design for Improved Patient Enrolment

The Anti-Fibrogenic and Liver Protective Effects of Namodenoson (CF102): From Preclinical to Human Studies

  • Pnina Fishman Chief Executive Officer & Chief Scientific Officer, Can-fite BioPharma


• Discover Namodenoson (CF102), an A3 adenosine receptor (A3AR) agonist known to induce antiinflammatory and protective effects in the liver
• Explore CF102 mechanism of action via down regulation of the Wnt and the NF-kB signa l transduction pathways, resulting in apoptosis of pathological cells
• Review the development of CF102 in Phase II clinical studies

IVA337: Effectively Targeting NASH


• IVA337 is a new chemical entity that activates the three PPAR (peroxisome proliferator-activated receptor) isoforms: α, δ and γ
• Evaluate the in vitro and in vivo preclinical development of IVA337, where IVA337 induced the regression of pre-existing fibrotic damage in the liver and prevented further fibrosis from developing
• Examine the latest clinical data which demonstrates efficacy of IVA337

Afternoon Refreshments & Networking

Looking Towards 2018: Advance Understanding of How the Field will Evolve

Panel Discussion: What Does the Next 12 Months Hold for NASH Therapeutic Development?


• Lessons learned from progress in the field during 2017
• What still needs to be done? How are we going to over come the main challenges?
• Speculation on developments for the next 12 months

Chair’s Closing Remarks

  • Peter Traber Chief Executive Officer & Chief Medical Officer, Galectin Therapeutics